Dutta Deep, Nagendra Lakshmi, Harish B G, Sharma Meha, Joshi Ameya, Hathur Basavanagowdappa, Kamrul-Hasan Abm
Department of Endocrinology, CEDAR Superspeciality Healthcare, Dwarka, New Delhi, India.
Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, Karnataka, India.
Indian J Endocrinol Metab. 2024 Sep-Oct;28(5):436-444. doi: 10.4103/ijem.ijem_45_24. Epub 2024 Sep 4.
No meta-analysis has analysed role of cagrilintide as weight-loss medication in obese individuals. Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator. Primary outcomes were changes in body weight; secondary outcomes were alterations in glycemia, lipids, and adverse events. From 678 articles, data from 3 RCTs involving 430 individuals were analysed. At 20-32 weeks, patients receiving Cagrisema weekly had significantly greater percentage [mean difference (MD)-9.07% (95%CI: -11.91, -6.23); < 0.00001; = 96%] and absolute [MD-9.11 kg (95%CI: -12.84, -5.39); < 0.00001; = 98%] weight-loss, compared to semaglutide 2.4 mg weekly. At 26-32 weeks, cagrilintide 2.4 mg had a similar percentage [MD - 1.83% (95%CI: -4.08, -0.42); = 0.11; = 98%] and absolute [MD - 1.88 kg (95%CI: -4.23,0.47); = 0.12; = 98%] weight-loss, compared to semaglutide/liraglutide. Treatment-emergent and serious adverse events were comparable between groups. Gastrointestinal adverse events and vomiting were significantly higher with Cagrisema compared to semaglutide. Vomiting was significantly lower with cagrilintide compared to semaglutide/liraglutide. Cagrisema outperforms semaglutide regarding weight loss. Cagrilintide shows comparable weight loss to semaglutide/liraglutide with significantly lower vomiting.
尚无荟萃分析研究卡格列净作为肥胖个体减肥药物的作用。检索电子数据库，查找涉及肥胖个体接受卡格列净或卡格列净2.4毫克与司美格鲁肽2.4毫克联合用药（Cagrisema）并与安慰剂/活性对照药进行比较的随机对照试验（RCT）。主要结局为体重变化；次要结局为血糖、血脂改变及不良事件。从678篇文章中，分析了3项涉及430名个体的随机对照试验数据。在20 - 32周时，与每周使用2.4毫克司美格鲁肽相比，每周接受Cagrisema治疗的患者体重减轻百分比显著更高[平均差值（MD）-9.07%（95%置信区间：-11.91，-6.23）；P<0.00001；I² = 96%]，且绝对体重减轻量更大[MD - 9.11千克（95%置信区间：-12.84，-5.39）；P<0.00001；I² = 98%]。在26 - 32周时，与司美格鲁肽/利拉鲁肽相比，2.4毫克卡格列净的体重减轻百分比[MD - 1.83%（95%置信区间：-4.08，-0.42）；P = 0.11；I² = 98%]和绝对体重减轻量[MD - 1.88千克（95%置信区间：-4.23，0.47）；P = 0.12；I² = 98%]相似。各治疗组出现的不良事件和严重不良事件相当。与司美格鲁肽相比，Cagrisema的胃肠道不良事件和呕吐发生率显著更高。与司美格鲁肽/利拉鲁肽相比，卡格列净的呕吐发生率显著更低。在减肥方面，Cagrisema优于司美格鲁肽。卡格列净的体重减轻效果与司美格鲁肽/利拉鲁肽相当，但呕吐发生率显著更低。
